Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jun Narita is active.

Publication


Featured researches published by Jun Narita.


International Journal of Cardiology | 2012

Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients

Hidekazu Ishida; Shigetoyo Kogaki; Hiroaki Ichimori; Jun Narita; Nobutoshi Nawa; Takayoshi Ueno; Kunihiko Takahashi; Futoshi Kayatani; Hidehumi Kishimoto; Masahiro Nakayama; Yoshiki Sawa; Maurice Beghetti; Keiichi Ozono

BACKGROUND Endothelin-1 (ET-1), a potent vasoconstrictor, is considered to be implicated in failing Fontan circulation, however the expressions of ET-1 and endothelin receptor type A (ET(A)R) and type B (ET(B)R) in the pulmonary arteries of failed Fontan patients were not elucidated. METHODS Immunohistochemistry and quantitative real-time PCR were used to analyse the expression levels of ET-1 and its receptors in the pulmonary arteries of the autopsy lung tissues of the patients who died after the Fontan procedure (n=10). We divided these patients into 3 groups, failed Fontan (n=4), heart failure (n=3) and non-failed Fontan (n=3), and then compared those to the age-matched normal controls (n=4). RESULTS The intra-acinar pulmonary arteries of failed Fontan patients showed significant medial hypertrophy. Computational optical density analyses of the immunostaining revealed that the expressions of ET-1, ET(A)R, and ET(B)R in the intra-acinar pulmonary arteries were significantly increased in the failed Fontan patients (P<0.05 vs. normal controls), however no significant difference was observed between the non-failed Fontan patients and the normal controls. Quantitative real-time PCR analyses confirmed that the mRNA expressions of ET-1, ET(A)R, and ET(B)R were significantly increased in the failed Fontan patients (P<0.05 vs. normal controls). CONCLUSION The overexpression of ET-1 and its receptors in the pulmonary arteries can cause pulmonary vasoconstriction and vascular remodelling, leading to failed Fontan circulation. This study suggests a histopathological rationale for the potential benefits of endothelin receptor antagonists in patients with failing Fontan circulation.


American Journal of Physiology-heart and Circulatory Physiology | 2011

LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling

Hidekazu Ishida; Shigetoyo Kogaki; Jun Narita; Hiroaki Ichimori; Nobutoshi Nawa; Yoko Okada; Kunihiko Takahashi; Keiichi Ozono

LEOPARD syndrome (LS) is an autosomal dominant inherited multisystemic disorder. Most cases involve mutations in the PTPN11 gene, which encodes the protein tyrosine phosphatase Src homology 2-containing protein phosphatase 2 (SHP2). LS frequently causes severe hypertrophic cardiomyopathy (HCM), even from the fetal period. However, the molecular pathogenesis has not been clearly elucidated. Here, we analyzed the roles of the LS-type SHP2 mutant Gln510Glu (Q510E), which showed the most severe type of HCM in LS, in cardiomyocyte differentiation, and in morphological changes. We generated mutant P19CL6 cell lines, the most convenient cardiomyocyte differentiation model, which continuously expressed SHP2-Q510E, SHP2-D61N (Noonan-type mutant), wild-type SHP2, and green fluorescent protein (native SHP2 expression only). SHP2-Q510E mutant P19CL6 cells showed significant attenuation of myofibrillogenesis, with increased proliferative activity. Mature cardiomyocytes from the SHP2-Q510E mutant were significantly larger than those of controls and the other mutants. However, expression of cardiac-specific transcriptional factors (Gata4, Tbx5, and Nkx2.5) did not differ significantly between the LS-type SHP2-Q510E mutants and the other mutants and controls. Our results indicate that SHP2-Q510E mutants can differentiate into cardiac progenitors but are inhibited from undergoing terminal differentiation into mature cardiomyocytes. In contrast, Akt and glycogen synthase kinase (GSK)-3β phosphorylation were upregulated, and nuclear β-catenin at the late stage of differentiation was highly accumulated in SHP2-Q510E mutant P19CL6 cells. Supplementation with the phosphoinositide 3-kinase/Akt inhibitor LY-294002 during the late stage of differentiation was found to partially restore myofibrillogenesis while suppressing the increase in size of individual mature cardiomyocytes derived from the SHP2-Q510E mutants. Our findings suggest that dysregulation of the Akt/GSK-3β/β-catenin pathway can contribute to the pathogenesis of HCM in LS patients, not only through hypertrophic changes in individual cardiac cells but also via the expansion of cardiac progenitors.


Molecular therapy. Methods & clinical development | 2016

Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension

Nobutoshi Nawa; Hidekazu Ishida; Shinichi Katsuragi; Hiroki Baden; Kunihiko Takahashi; Ryota Higeno; Fumiko Torigoe; Seiko Mihara; Jun Narita; Kohji Miura; Kazufumi Nakamura; Shigetoyo Kogaki; Keiichi Ozono

We recently found a constitutively active mutant of natriuretic peptide receptor 2 (caNPR2; V883M), which synthesizes larger amounts of cyclic guanosine monophosphate (cGMP) intracellularly without any ligand stimulation than existing drugs. The aim of this study was to investigate the therapeutic effects of gene transduction using caNPR2 for pulmonary arterial hypertension (PAH). In vitro gene transduction into human pulmonary arterial smooth muscle cells using Sendai virus (SeV) vectors carrying caNPR2 induced 10,000-fold increases in the synthesis of cGMP without ligand stimulation, and the proliferation of caNPR2-expressing cells was significantly attenuated. The PAH model rats generated by hypoxia and the administration of SU5416 were then treated with SeV vectors through a direct injection into the left pulmonary artery. Right ventricular systolic pressure was significantly decreased 2 weeks after the treatment, while systemic blood pressure remained unchanged. Histological analyses revealed that the medial wall thickness and occlusion rate of pulmonary arterioles were significantly improved in caNPR2-treated lungs. Neither the systemic integration of virus vectors nor side effects were observed. The massive stimulation of cGMP synthesis by gene therapy with caNPR2 was safe and effective in a PAH rat model and, thus, has potential as a novel therapy for patients with severe progressive PAH.


American Journal of Transplantation | 2018

Analysis of public discourse on heart transplantation in Japan using social network service data

Nobutoshi Nawa; Hidekazu Ishida; H. Suginobe; Shinichi Katsuragi; Hiroki Baden; Kunihiko Takahashi; Jun Narita; Shigetoyo Kogaki; Keiichi Ozono

The clarification of public concerns regarding heart transplantation is important for improving low organ donation rates in Japan. In the present study, we used the Twitter data of 4986 tweets (between August 2015 and January 2016) and 1429 tweets (between April 2016 and May 2016) to analyze public discourse on heart transplantation in Japan and identify the reasons for low organ donation rates. We manually categorized all tweets relevant to heart transplantation into nine categories and counted the number of tweets in each category per month. During the study period, the most popular category of tweets was related to the media, followed by money (tweets questioning or even criticizing the high price of fundraising goals to go overseas for heart transplantations), while some tweets were misconceptions. We also conducted a sentiment analysis, which revealed that the most popular negative tweets were related to money, while the most positive tweets were related to reports on the favorable outcomes of recipients. Our results suggest that listening to concerns, providing correct information (particularly for some misconceptions), and emphasizing the outcomes of recipients will facilitate an increase in the number of people contemplating heart transplantation and organ donation.


Circulation | 2013

Drastic Shift From Positive to Negative Estrogen Effect on Bone Morphogenetic Protein Signaling in Pulmonary Arterial Endothelial Cells Under Hypoxia

Hiroaki Ichimori; Shigetoyo Kogaki; Kunihiko Takahashi; Hidekazu Ishida; Jun Narita; Nobutoshi Nawa; Hiroki Baden; Toshiki Uchikawa; Yoko Okada; Keiichi Ozono


Circulation | 2015

Abstract 16716: Intravascular Injection of Sendai Virus Vector Carrying Continuously cGMP Producing Mutant of Type B Natriuretic Peptide Receptor Can Ameliorate Pulmonary Arterial Hypertension

Nobutoshi Nawa; Hidekazu Ishida; Shinichi Katuragi; Hiroki Baden; Kunihiko Takahashi; Sigetoyo Kogaki; Ryota Higeno; Fumiko Torigoe; Seiko Mihara; Jun Narita; Koji Miura; Keiichi Ozono


Blood | 2015

Clinical Characteristic and Prognosis of Post-Transplant Lymphoproliferative Disorder in Pediatric Heart Transplant Recipients in Japan

Takako Miyamura; Yoshiko Hashii; Norihide Fukushima; Shigetoyo Kogaki; Hisao Yoshida; Kunihiko Takahashi; Jun Narita; Keiichi Ozono


american thoracic society international conference | 2011

Augmentation Of Bone Morphogenetic Protein Signaling Prevents Adverse Effect Of Hypoxia On Endothelin And Nitric Oxide Pathways In Pulmonary Artery Endothelial Cells

Hiroaki Ichimori; Shigetoyo Kogaki; Kunihiko Takahashi; Jun Narita; Hidekazu Ishida; Nobutoshi Nawa; Keiichi Ozono


The Journal of the Japan Pediatric Society | 2011

Clinical Features of the 19 Japanese Pediatric Patients after Heart Transplantation

Hidekazu Ishida; Shigetoyo Kogaki; Hiroaki Ichimori; Jun Narita; Toshiki Uchikawa; Shu Maekawa; Sayaka Matsumoto; Yoko Okada; Keiichi Ozono


Circulation | 2011

Abstract 15073: Type B Human Natriuretic Peptide Receptor with a novel gain-of-function mutation provides therapeutic potential in the treatment of pulmonary arterial hypertension

Nobutoshi Nawa; Hidekazu Ishida; Sigetoyo Kogaki; Toshiki Uchikawa; Yoko Okada; Jun Narita; Shu Maekawa; Hiroaki Ichimori; Seiko Mihara; Hiroki Baden; Shinichi Katuragi; Koji Miura; Keiichi Ozono

Collaboration


Dive into the Jun Narita's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge